comparemela.com
Home
Live Updates
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 : comparemela.com
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Related Keywords
Copenhagen ,
Køavn ,
Denmark ,
Ukraine ,
Russia ,
Franziska Burianek ,
Edna Kaplan ,
Daniel Vitt ,
Paula Schwartz ,
Jessica Breu ,
Exchange Commission ,
Rx Communications Group ,
Immunic Inc ,
Nasdaq ,
United European Gastroenterology Week ,
Chief Executive Officer ,
Human Trial ,
Barrier Regeneration ,
Senior Medical Director ,
Moderated Posters ,
Poster Stage ,
Private Securities Litigation Reform Act ,
Annual Report ,
Investor Relations ,
Immunic ,
Nc ,
comparemela.com © 2020. All Rights Reserved.